Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:
Consumer OTC Drugs

NCI Phase III Trial On Shark Cartilage May Begin Recruitment Summer/Fall

This article was originally published in The Tan Sheet

  • News
  • The Tan Sheet

Executive Summary

A National Cancer Institute Phase III trial on the effects of shark cartilage on stages 3a and 3b inoperable non-small cell lung cancer may begin recruitment in the late summer or early fall.

You may also be interested in...



Lane Labs FTC Settlement To Fund National Cancer Institute Study

Lane Labs has been ordered by the Federal Trade Commission to contribute $450,000 to fund a National Cancer Institute clinical study on the effects of shark cartilage supplementation on cancer as part of a $1 mil. settlement of charges it made unsubstantiated cancer claims for its dietary supplements.

Lane Labs FTC Settlement To Fund National Cancer Institute Study

Lane Labs has been ordered by the Federal Trade Commission to contribute $450,000 to fund a National Cancer Institute clinical study on the effects of shark cartilage supplementation on cancer as part of a $1 mil. settlement of charges it made unsubstantiated cancer claims for its dietary supplements.

Lane Labs FTC Settlement To Fund National Cancer Institute Study

Lane Labs has been ordered by the Federal Trade Commission to contribute $450,000 to fund a National Cancer Institute clinical study on the effects of shark cartilage supplementation on cancer as part of a $1 mil. settlement of charges it made unsubstantiated cancer claims for its dietary supplements.

Table

View full table

Related Content

HBW Insight
Pink Sheet
HBW Insight

Topics

Tags:
Consumer OTC Drugs
UsernamePublicRestriction

Register

LL111799

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By